Does LENT Prognostic Score Predict Mortality? An Observational Study Does LENT Prognostic Score Predict Mortality

Abstract

Aim: Determining the patients with long survival helps determine the best prevention strategies such as pleurodesis or tunneled pleural catheter, providing better palliation by minimizing the symptoms and morbidities associated with MPE relapse. This study aims to evaluate the predictive strength of LENT, a current prognostic score for MPE patients, and determine its effect on survival and importance in clinical decision-making. Material and Methods: MPE patients between 2008 and 2020 were examined retrospectively. Age, sex, type of cancer, histological type, LDH, blood Neutrophil/ Lymphocyte values were taken, and ECOG, biopsy, and survival rates were calculated. Survival time was calculated as the period between thoracentesis result and death. Results: The study group consisted of 268 MPE patients, and the average age of patients was 65.3 +/- 13.2 years, and 58.2% of the patients were male. Patients with high-risk LENT scores were observed to have 2.8 times more risk compared to the low-risk patients within the period of observation (Hazard Ratio:2.836, p:0.001). The median survival time for moderate-risk patients was shorter than for low-risk group (450 vs. 623 days). Discussion: The LENT prognostic score is a simple score that can be used on patients suitable for pleural fluid analysis and significantly better than the Eastern Cooperative Oncology Group performance score (ECOG PS) for predicting survival. It is considered to be used conveniently to guide MPE treatments.